
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed has demonstrated significant operational efficiencies, with its gross margin increasing 230 basis points year-over-year to reach 59.2%, driven by improved pricing, manufacturing efficiencies, and lower component costs. Additionally, the company's respiratory sales in the Americas grew 12% to $749 million, showcasing resilience in a competitive market, while overall expectations for future patient growth remain strong, with 89% of healthcare practitioners anticipating an increase in CPAP patients. Despite potential slowdowns in revenue growth, the strategic shift towards improved product mix and digital health innovations positions ResMed favorably to enhance its operating margins further in the coming years.
Bears say
ResMed's financial outlook appears negative due to several key factors impacting its revenue and margins. The company is facing potential market share loss, particularly with competitors like Philips re-entering the flow generator market, coupled with headwinds from emerging GLP-1 weight loss drugs that may reduce treatment adherence among sleep apnea patients. Additionally, despite a recent organic revenue growth rate of 10% in F2Q25, the deceleration from the previous quarter's 11% raises concerns about future performance, particularly as margin pressures and a lowered earnings estimate for FY27 suggest challenges ahead.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares